Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intranasal dexmedetomidine with or without esketamine for sedation during cervical cancer brachytherapy
ChiCTR2200063146Phase 4Not yet recruiting
- Sponsor
- Third People's Hospital of Chengdu
- Start
- Sep 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of dexmedetomidine and esketamine in Cervical Cancer (CC) (2 arms), sponsored by Third People's Hospital of Chengdu. Primary endpoints: Modified Observer's Assessment of Alertness and Visual analogue scale pain score. Planned start Sep 2022; status: not yet recruiting.
02
Drugs
dexmedetomidineesketamine
03
Conditions
Cervical Cancer (CC)
Beyond the preview
Go deeper on ChiCTR2200063146.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200063146.